Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

nformation about Oncolytics please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2008 and beyond, the Company's planned expansion, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the ability of the technology to strengthen the core technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs and the Company's planned expansion of such programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statemen
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the report ... Companies " to their offering. ... briefly reviews basics of human genome variations, ... Current large and small sequencers are described ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Cardium Therapeutics (NYSE Amex: CXM ) today ... the U.S. Food and Drug Administration (FDA) seeking marketing ... Excellagen XL is an advanced wound care management ... designed for use by physicians in patients with topical ...
... DUBLIN, Ireland, November 2 The Board of,Directors of ... Mr David,Stout joined the Board as a Non Executive Director ... Mr Stout has extensive pharmaceutical experience. Most recently he was,President, ... pharmaceutical operations in the United States, Europe,Japan and all other ...
... successful phase III trial points to the first new lupus ... 2 The Lupus Research Institute (LRI) and its National ... Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - ... the first successfully tested new drug developed specifically for people ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4New Shire Board Member 2Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus 2
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further ... gastroenterology with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes ... "In its third year, this competition continues to grow ... promising careers in basic and clinical research," said Nicholas ... Foundation. "We are extremely proud of all that these ...
(Date:6/16/2013)... programs for female sex workers in India reduce rates ... a University of Toronto study has found. ... mostly in the southern states of Andhra Pradesh, Karnataka, ... Prabhat Jha from U of T,s Dalla Lana School ... Global Health Research (CGHR), examined the impact of prevention ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... and the environment will gather in Nairobi, Kenya this ... cycle of drought and food insecurity. The Beating Famine ... the Sahel region of Africa, this time through Niger, ... will take place on April 10-13 at the World ...
... 2012 The Canadian Journal of Cardiology ... Society,s atrial fibrillation guidelines. Atrial fibrillation is the ... stroke, illness in general, and death. It is, for example, ... year has seen important changes in the drugs available to ...
... known for its role in embryonic development and cancer ... or scleroderma, therapy. The finding, discovered by a cross-disciplinary ... Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg ... Arthritis & Rheumatism. "We showed, for ...
Cached Biology News:Beating famine: Sustainable food security through land regeneration in a changing climate 2New genetic path for scleroderma 2
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: